QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
NASDAQ:MDWD

MediWound - MDWD Stock Forecast, Price & News

$1.77
-0.03 (-1.67%)
(As of 08/9/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.75
$1.83
50-Day Range
$1.33
$1.87
52-Week Range
$1.21
$4.01
Volume
49,327 shs
Average Volume
114,719 shs
Market Capitalization
$58.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.13

MediWound MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
302.5% Upside
$7.13 Price Target
Short Interest
Healthy
0.91% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.20mentions of MediWound in the last 14 days
Based on 18 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.37) to ($0.27) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.96 out of 5 stars

Medical Sector

709th out of 1,098 stocks

Medicinals & Botanicals Industry

7th out of 13 stocks

MDWD stock logo

About MediWound (NASDAQ:MDWD) Stock

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.

MediWound Stock Down 2.7 %

Shares of NASDAQ:MDWD opened at $1.80 on Tuesday. MediWound has a fifty-two week low of $1.21 and a fifty-two week high of $4.01. The firm has a 50-day simple moving average of $1.71 and a 200 day simple moving average of $1.95.

MediWound (NASDAQ:MDWD - Get Rating) last announced its quarterly earnings data on Tuesday, May 17th. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.01). MediWound had a negative net margin of 64.01% and a negative return on equity of 3,540.43%. The business had revenue of $4.41 million for the quarter, compared to the consensus estimate of $4.35 million. During the same period in the prior year, the company earned ($0.10) EPS. As a group, analysts expect that MediWound will post -0.37 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on MDWD shares. Wells Fargo & Company lifted their price target on shares of MediWound to $8.00 and gave the stock an "overweight" rating in a research note on Wednesday, May 18th. Oppenheimer reaffirmed an "outperform" rating and set a $7.00 price target on shares of MediWound in a research note on Monday, July 18th. Finally, StockNews.com started coverage on shares of MediWound in a research report on Tuesday. They issued a "sell" rating for the company. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat, MediWound currently has an average rating of "Moderate Buy" and a consensus price target of $7.13.

Receive MDWD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MediWound and its competitors with MarketBeat's FREE daily newsletter.

MDWD Stock News Headlines

MediWound (MDWD) Set to Announce Quarterly Earnings on Tuesday
See More Headlines
Receive MDWD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MediWound and its competitors with MarketBeat's FREE daily newsletter.

MDWD Company Calendar

Last Earnings
5/17/2022
Today
8/09/2022
Next Earnings (Confirmed)
8/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Medicinals & botanicals
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MDWD
Employees
77
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.13
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$6.50
Forecasted Upside/Downside
+302.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-13,550,000.00
Pretax Margin
-63.87%

Debt

Sales & Book Value

Annual Sales
$23.76 million
Book Value
($0.17) per share

Miscellaneous

Free Float
N/A
Market Cap
$58.66 million
Optionable
Not Optionable
Beta
1.05

Key Executives

  • Prof. Lior Rosenberg M.D. (Age 76)
    Co-Founder & Chief Medical Technology Officer
    Comp: $398k
  • Mr. Boaz Gur-Lavie CPA (Age 48)
    M.B.A., Chief Financial Officer
    Comp: $309k
  • Mr. Yaron Meyer Adv. (Age 43)
    Exec. VP, Gen. Counsel & Corp. Sec.
    Comp: $240k
  • Dr. Ety Klinger (Age 60)
    Chief R&D Officer
    Comp: $344k
  • Mr. Stephen T. Wills CPA (Age 65)
    CPA, MST, Exec. Chairman
  • Mr. Ofer Gonen B.Sc. (Age 49)
    CEO & Director













MDWD Stock - Frequently Asked Questions

Should I buy or sell MediWound stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MediWound in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MDWD shares.
View MDWD analyst ratings
or view top-rated stocks.

What is MediWound's stock price forecast for 2022?

4 brokerages have issued 1-year price targets for MediWound's shares. Their MDWD share price forecasts range from $6.50 to $8.00. On average, they expect the company's stock price to reach $7.13 in the next twelve months. This suggests a possible upside of 293.6% from the stock's current price.
View analysts price targets for MDWD
or view top-rated stocks among Wall Street analysts.

How has MediWound's stock performed in 2022?

MediWound's stock was trading at $2.36 at the beginning of 2022. Since then, MDWD shares have decreased by 23.3% and is now trading at $1.81.
View the best growth stocks for 2022 here
.

Are investors shorting MediWound?

MediWound saw a increase in short interest in July. As of July 15th, there was short interest totaling 176,700 shares, an increase of 259.9% from the June 30th total of 49,100 shares. Based on an average daily volume of 106,000 shares, the short-interest ratio is presently 1.7 days. Currently, 0.9% of the company's stock are short sold.
View MediWound's Short Interest
.

When is MediWound's next earnings date?

MediWound is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022.
View our MDWD earnings forecast
.

How were MediWound's earnings last quarter?

MediWound Ltd. (NASDAQ:MDWD) posted its quarterly earnings data on Tuesday, May, 17th. The biopharmaceutical company reported ($0.12) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by $0.01. The biopharmaceutical company earned $4.41 million during the quarter, compared to analysts' expectations of $4.35 million. MediWound had a negative net margin of 64.01% and a negative trailing twelve-month return on equity of 3,540.43%. During the same period in the previous year, the company earned ($0.10) earnings per share.

What other stocks do shareholders of MediWound own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MediWound investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), Blackstone (BX), Dynavax Technologies (DVAX), Geron (GERN), Idera Pharmaceuticals (IDRA), Mastercard (MA), SCYNEXIS (SCYX), Vascular Biogenics (VBLT) and Wells Fargo & Company (WFC).

What is MediWound's stock symbol?

MediWound trades on the NASDAQ under the ticker symbol "MDWD."

Who are MediWound's major shareholders?

MediWound's stock is owned by a variety of retail and institutional investors. Top institutional investors include Sargent Investment Group LLC (1.58%) and Meitav Dash Investments Ltd. (0.85%).

How do I buy shares of MediWound?

Shares of MDWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MediWound's stock price today?

One share of MDWD stock can currently be purchased for approximately $1.81.

How much money does MediWound make?

MediWound (NASDAQ:MDWD) has a market capitalization of $59.98 million and generates $23.76 million in revenue each year. The biopharmaceutical company earns $-13,550,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis.

How many employees does MediWound have?

MediWound employs 77 workers across the globe.

How can I contact MediWound?

MediWound's mailing address is 42 HAYARKON STREET, YAVNE L3, 8122745. The official website for the company is www.mediwound.com. The biopharmaceutical company can be reached via phone at 972779714100, via email at afields@lhai.com, or via fax at 972-77-971-4111.

This page (NASDAQ:MDWD) was last updated on 8/9/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.